AtriCure, Inc. 10-Q Filing Summary
Business Context and Reporting Period
Company: AtriCure, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: AtriCure develops, manufactures, and sells medical devices for cardiac ablation, primarily the Isolator bipolar ablation system used to treat atrial fibrillation (AF). The company operates in a single segment with sales in the United States and internationally (primarily Europe, Asia, South America, and Canada).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2008 |
Six Months Ended June 30, 2008 |
|---|---|---|
| Revenues | $14,858,514 | $28,388,659 |
| Gross Profit | $11,363,606 (76.5% margin) | $21,662,871 (76.3% margin) |
| Net Loss | $(1,592,616) | $(5,198,047) |
| Loss Per Share (Basic/Diluted) | $(0.11) | $(0.37) |
| Cash and Cash Equivalents | $10,023,442 | $10,023,442 |
| Short-Term Investments | $1,895,462 | $1,895,462 |
| Total Debt (Current + Long-Term) | $571,387 | $571,387 |
| Working Capital | $21,175,437 | $21,175,437 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 20.3% ($2.5M) for the three months and 22.9% ($5.3M) for the six months ended June 30, 2008, compared to the same periods in 2007. Growth was driven by increased unit sales of existing products and the introduction of new products (ORlab mapping system and Coolrail linear ablation device).
- Margin Compression: Gross margin decreased from 79.4% to 76.5% (three months) and 79.4% to 76.3% (six months). This was attributed to the sale of the ORlab system, which has a higher cost of revenue than disposable products, and a higher mix of international sales with lower average selling prices.
- Operating Expenses:
- R&D: Decreased by 11.4% (three months) and 17.0% (six months) due to the redeployment of clinical staff to sales roles in 2007.
- Selling, General & Administrative (SG&A): Increased by 5.6% (three months) and 10.0% (six months) primarily due to headcount-related selling expenses.
- Net Loss Improvement: Net loss narrowed significantly, decreasing 42.8% for the three months and 26.7% for the six months compared to the prior year periods.
- Cash Flow: Net cash used in operating activities increased to $6.5M (six months 2008) from $5.6M (six months 2007), driven by the net loss and increases in accounts receivable and inventory.
Guidance, Outlook, and Risks
- Clinical Trials: The company is conducting the ABLATE pivotal clinical trial for the Isolator system to treat permanent and persistent AF. FDA approval is targeted for as early as 2010 if trials are successful. Enrollment for a second arm (persistent AF) is expected to begin in the second half of 2008.
- New Product Launches: The company plans to release a new disposable cryoablation probe in the second half of 2008. A clinical trial for a left atrial appendage exclusion system is also expected to begin enrollment in the second half of 2008.
- Seasonality: Management notes a typical sequential revenue decline in the third quarter due to the elective nature of cardiac procedures during summer months.
- Liquidity: The company believes current cash and equivalents ($11.9M total liquid assets) are sufficient for at least the next 12 months. On July 1, 2008, the company entered a new $10M credit facility with National City Bank and paid off its previous $0.5M debt to Lighthouse Capital Partners.
- Risks:
- Regulatory: Products are cleared for tissue ablation but not specifically for the treatment of AF; marketing is restricted to cleared indications.
- Legal: A securities class action lawsuit (Levine v. AtriCure, Inc.) remains pending regarding the 2005 IPO.
- Financial: The company has an accumulated deficit of $72.5M and relies on future product approvals and market acceptance to achieve profitability.
Key Facts for Investor Verification
- Cash Position: Verify the sustainability of the $11.9M cash/investment balance against the $6.5M operating cash burn rate for the first half of the year.
- Product Mix Impact: Monitor the impact of the new ORlab system on gross margins, as it currently exerts downward pressure on overall profitability.
- Credit Facility Covenants: Review the new National City Bank agreement (July 2008) which includes a financial covenant limiting annual pre-tax loss (EBITDA) to $15M and requires maintaining a restricted cash account.
- Clinical Trial Progress: Track enrollment and results of the ABLATE trial and the left atrial appendage exclusion system trial, as FDA approval for AF treatment is critical for long-term growth.
- Accounts Receivable: Accounts receivable increased by $2.2M in the first half of 2008; verify collection trends and allowance for doubtful accounts.